Alexander Stewart
Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alexander Stewart as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:44 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT00719901 · Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaNational Cancer Institute (NCI) · terminated · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 1 - High Throughtput Drug Screening and Correlations with Mutational Status in Myeloma Cell Lines and Patient SamplesU54CA224018 · NCI · MAYO CLINIC ARIZONA · fiscal years 2017 to 2020 · $332,666 awarded in 2020Same name and institution; not confirmed by an ID
- Clonal Evolution in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · fiscal years 2015 to 2019 · $254,798 awarded in 2019Same name and institution; not confirmed by an ID
- The Role of Cereblon Pathways in MyelomaR01CA183968 · NCI · MAYO CLINIC ARIZONA · fiscal years 2014 to 2018 · $446,267 awarded in 2018Same name and institution; not confirmed by an ID
- Translation of Novel Therapeutic Targets in Multiple MyelomaR01CA167511 · NCI · MAYO CLINIC ARIZONA · fiscal years 2013 to 2017 · $431,907 awarded in 2017Same name and institution; not confirmed by an ID
- A Genome Wide RNAi Vulnerability Map for MyelomaR01CA133115 · NCI · MAYO CLINIC ARIZONA · fiscal years 2008 to 2012 · $246,800 awarded in 2012Same name and institution; not confirmed by an ID
- The Molecular Basis for Bortezomib ActivityR01CA129009 · NCI · MAYO CLINIC ARIZONA · fiscal years 2007 to 2011 · $295,041 awarded in 2011Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- P01CA136447RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00719901
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:44 UTC. The ranking covers the 200 most relevant of 65 PubMed records, and a shared surname and initials can bring in a namesake. All 65 on PubMed
- 1,575 citationsRCR 84.7
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.N Engl J Med · 20151,133 citationsRCR 36.3
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med · 2019550 citationsRCR 19.6
- 537 citationsRCR 14.4
- 364 citationsRCR 10.0
- 316 citationsRCR 7.3
- Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.J Clin Oncol · 2009243 citationsRCR 5.3
- A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.Clin Cancer Res · 2009238 citationsRCR 5.2
- Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial.Ann Intern Med · 2005237 citationsRCR 6.4
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.J Clin Oncol · 2018237 citationsRCR 8.6